69 results
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
include research and development (“R&D”) costs and general and administrative (“G&A”) expenses, were $4.0 million in the Fiscal 2024 Quarter, compared … to $4.8 million in the Fiscal 2023 Quarter, a decrease of $0.8 million, which is discussed more fully below.
R&D costs increased slightly
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
period associated with the Committed Purchase (as defined below).
Operating expenses, which include R&D and general and administrative (“G&A”) expenses … ended December 31,
In 000’$
Research and development
General and administrative expenses
Total operating expenses
Research and Development Costs
R&D costs
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
, which include R&D and general and administrative (“G&A”) expenses, were $4.0 million in the Fiscal 2024 Quarter, compared to $4.8 million in the Fiscal …
Total operating expenses
Research and Development Costs
R&D costs are comprised of the following:
Three months ended December 31,
In 000’$
Research
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
:
Operating expenses, which include R&D and general and administrative (“G&A”) expenses, were $5.9 million in the Fiscal 2024 Quarter, compared to $3.6 … expenses
Research and Development Costs
R&D costs are comprised of the following:
Three months ended September 30,
In 000’$
Research and development
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Nov 23
PORT 2 and 6 Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
4:02pm
million, which is discussed more fully below.
R&D costs increased by approximately $2.7 million to approximately $4.2 million, or approximately 180 … ). These increases in R&D costs reflect the clinical activity and manufacturing-related costs related to developing the Company’s adenosine and iNKT
6-K
EX-99.2
ns6tk9v99 l41wbax9
28 Nov 23
Current report (foreign)
4:01pm
424B5
wr305
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
hpmz0lpb6et2n apoyp1
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
ccqw7aarrnp3vksl
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
0v7nsgmy3rlq8pp
31 Jul 23
Current report (foreign)
6:10pm
6-K
EX-99.2
bw42h7m9vh g8cjnio
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.2
li3hbfddk hb5l7xt
29 Aug 22
Current report (foreign)
4:00pm
6-K
EX-99.1
lej oxdczpiiq6
1 Aug 22
Current report (foreign)
4:48pm
6-K
EX-99.2
lpwvzljascxj
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
rjthg78
25 Feb 22
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
12:00am
6-K
EX-99.2
oyw11s9va43ey3r2qe
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.1
z4gx1rwzibs4j7a8
23 Nov 21
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
8:00am
6-K
EX-99.2
hnr53axwx 18auvh5
30 Aug 21
Current report (foreign)
5:21pm